Investing

Add as a preferred source on Google

Johnson & Johnson Shares Show Investors’ Shift to Defensive U.S. Stocks

CNBC reported the shares reached a record intraday high Monday before retreating. Its figures show health care and consumer staples rising as technology and the S&P 500 fell over the past month.

Updated 2 min read
Pedestrians pass the Johnson & Johnson headquarters campus in New Brunswick, New Jersey. / EconoTimes.ai
Pedestrians pass the Johnson & Johnson headquarters campus in New Brunswick, New Jersey. / EconoTimes.ai

Johnson & Johnson is offering a window into investors’ move toward defensive U.S. stocks, CNBC reported, as technology shares have fallen and defensive sectors have led the market over the past month.

CNBC Investing Club host Jim Cramer called J&J a “metaphor for what’s working” on Monday, Nov. 16. J&J had finished Friday at a record closing high, then reached a further intraday peak Monday before losing ground, CNBC reported.

The outlet’s figures showed health care and consumer staples gaining 7% and 6%, respectively, over the past month. Technology fell more than 9% in the same period, while the S&P 500 lost nearly 3%. CNBC linked technology’s decline to concerns about what a Democratic wave could mean for data-center construction.

CNBC said the Investing Club had been trimming data-center exposure and adding defensive holdings in recent weeks. EconoTimes previously covered Cramer’s plans to reduce data-center exposure after the midterm vote.

CNBC reported that J&J had announced an agreement to acquire clinical-stage biopharmaceutical company Ollin Biosciences for $2.2 billion upfront, with as much as $1.13 billion more if certain milestones are met. The deal would expand J&J’s treatments for serious eye diseases, the outlet reported.

Cramer has pointed to J&J’s drug pipeline, including its blood cancer treatments and Icotyde, an oral treatment for plaque psoriasis, CNBC reported. The outlet also said J&J exceeded third-quarter revenue and earnings expectations in October, but its shares fell nearly 6% amid weaker MedTech performance.

J&J plans to spin off its orthopedics business by 2027. CNBC disclosed that Jim Cramer’s Charitable Trust holds a long position in J&J and said the shares had gained 20% since the Investing Club began its position in early April.

Related articles

View all